Regioselective Suzuki coupling of dihaloheteroaromatic compounds as a rapid strategy to synthesize potent rigid combretastatin analogues

Journal of Medicinal Chemistry

Volumn 54, Issue 14, 2011, Pages 4977-4986

  Theeramunkong, Sewan ^a   Caldarelli, Antonio ^a   Massarotti, Alberto ^a   Aprile, Silvio ^a   Caprioglio, Diego ^a   Zaninetti, Roberta ^a   Teruggi, Alessia ^a   Pirali, Tracey ^a   Grosa, Giorgio ^a   Tron, Gian Cesare ^a   Genazzani, Armando A ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 METHOXYPHENYL) 3 (3,4,5 TRIMETHOXYPHENYL)FURAN; 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL) 3 FURYL]PHENOL; 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)CYCLOPENT 1 EN 1 YL]PHENOL; 2 METHOXY 5 [3 (3,4,5 TRIMETHOXYPHENYL) 2 FURYL]PHENOL; 3 (4 METHOXYPHENYL) 2 (3,4,5 TRIMETHOXYPHENYL)FURAN; 3 BROMO 2 (4 METHOXYPHENYL)FURAN; ALICYCLIC COMPOUND; AROMATIC COMPOUND; COMBRETASTATIN; COMBRETASTATIN A4; CYCLOPENTENE DERIVATIVE; FURAN DERIVATIVE; THIOPHENE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CYTOTOXICITY; DRUG METABOLISM; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; MICROTUBULE ASSEMBLY; PHARMACODYNAMICS; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; SUZUKI REACTION;

ANTINEOPLASTIC AGENTS; BINDING SITES; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; COLCHICINE; DRUG SCREENING ASSAYS, ANTITUMOR; FURANS; HUMANS; INHIBITORY CONCENTRATION 50; MICROSOMES, LIVER; MODELS, MOLECULAR; STEREOISOMERISM; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN; TUBULIN MODULATORS;

EID: 79960627839     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200555r     Document Type: Article

References (33)

1. Pettit, G. R.; Singh, S. B.; Hamel, E.; Lin, C. M.; Alberts, D. S. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4 Experientia 1989, 45, 209-211 (Pubitemid 19062390)
2. Bibby, M. C. Combretastatin anticancer drugs Drugs Future 2002, 27, 475-480 (Pubitemid 34815035)
3. Pinney, K. G.; Jelinek, C.; Edvardsen, K.; Chaplin, D. J.; Pettit, G. R. The Discovery and Development of the Combretastatins. In Antitumor Agents from Natural Products; Kingston, D.; Newman, D.; Cragg, G., Eds.; CRC Press: Boca Raton, FL, 2005; pp 23-46.
4. Kanthou, C.; Tozer, G. M. The tumor vascular targeting agent combretastatin A-4 phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells Blood 2002, 99, 2060-2069 (Pubitemid 34525489)
5. Chaplin, D. J.; Hill, S. A. The development of combretastatin A-4 phosphate as a vascular targeting agent Int. J. Radiat. Oncol., Biol., Phys. 2002, 54, 1491-1496 (Pubitemid 35380054)
6. West, C. M. L.; Price, P. Combretastatin A4 phosphate Anti-Cancer Drugs 2004, 15, 179-186
7. Siemann, D. W.; Chaplin, D. J.; Walicke, P. A. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P) Expert Opin. Invest. Drugs 2009, 18, 189-197
8. Delmonte, A.; Sessa, C. AVE8062: a new combretastatin derivative vascular disrupting agent Expert Opin. Invest. Drugs 2009, 18, 1541-1548
9. Tron, G. C.; Pirali, T.; Sorba, G.; Pagliai, F.; Busacca, S.; Genazzani, A. A. Medicinal chemistry of combretastatin A4: present and future directions J. Med. Chem. 2006, 49, 3033-3044 (Pubitemid 43830499)
10. Gaukroger, K.; Hadfield, J. A.; Lawrence, N. J.; Nlan, S.; McGown, A. T. Structural requirements for the interaction of combretastatins with tubulin: How important is the trimethoxy unit? Org. Biomol. Chem. 2003, 1, 3033-3037
11. Beale, T. M.; Myers, R. M.; Shearman, J. W.; Charnock-Jones, D. S.; Brenton, J. D.; Gergely, F. V.; Ley, S. V. Med. Chem. Commun. 2010, 1, 202-208
12. Aprile, S.; Del Grosso, E.; Tron, G. C.; Grosa, G. In vitro metabolism study of combretastatin A-4 in rat and human liver microsomes Drug Metab. Dispos. 2007, 35, 2252-2261 (Pubitemid 350146212)
13. Nam, N.-H. Combretastatin A-4 analogues as antimitotic antitumor agents Curr. Med. Chem. 2003, 10, 1697-1722 (Pubitemid 37038595)
14. Hsieh, H. P.; Liou, J. P.; Mahindroo, N. Curr. Pharm. Des. 2005, 11, 1655-1677
15. Chaudari, A.; Pandeya, S. N.; Kumar, P.; Sharma, P. P.; Gupta, S.; Soni, N.; Verma, K. K.; Bhardwaj, G. Combretastatin A-4 analogues as anticancer agents Mini-Rev. Med. Chem. 2007, 12, 1186-1205 (Pubitemid 350303084)
16. Pirali, T.; Busacca, S.; Beltrami, L.; Imovilli, D.; Pagliai, F.; Miglio, G.; Massarotti, A.; Verotta, L.; Tron, G. C.; Sorba, G.; Genazzani, A. A. Synthesis and cytotoxic evaluation of combretafurans, potential scaffolds for dual-action antitumoral agents J. Med. Chem. 2006, 49, 5372-5376 (Pubitemid 44260231)
17. Cafici, L.; Pirali, T.; Condorelli, F.; Del Grosso, E.; Massarotti, A.; Sorba, G.; Canonico, P. L.; Tron, G. C.; Genazzani, A. A. Solution-phase parallel synthesis and biological evaluation of combretatriazoles J. Comb. Chem. 2008, 10, 732-740
18. Romagnoli, R.; Baraldi, P. G.; Cruz-Lopez, O.; Lopez Cara, C.; Carrion, M. D.; Brancale, A.; Hamel, E.; Chen, L.; Bortolozzi, R.; Basso, G.; Viola, G. Synthesis and antitumor activity of 1,5-disubstituted 1,2,4-triazoles as cis-restricted combretastatin analogues J. Med. Chem. 2010, 53, 4248-4258
19. Wang, L.; Woods, K. W.; Li, Q.; Barr, K. J.; McCroskey, R. W.; Hannick, S. M.; Gherke, L.; Credo, R. B.; Hui, Y.-H.; Marsh, K.; Warner, R.; Lee, J. Y.; Zielinski-Mozng, N.; Frost, D.; Rosemberg, S. H.; Sharm, H. L. Potent orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity J. Med. Chem. 2002, 45, 1697-1711 (Pubitemid 34293536)
20. Ohsumi, K.; Hatanaka, T.; Fujita, K.; Nakagawa, R.; Fukuda, Y.; Nihei, Y.; Suga, Y.; Morinaga, Y.; Akiyama, Y.; Tsuji, T. Bioorg. Med. Chem. Lett. 1998, 8, 3153-3158
21. Cushman, M.; Nagarathnam, D.; Gopal, D.; He, H.-M.; Lin, C. M.; Hamel, E. J. Med. Chem. 1992, 35, 2293-2306
22. Gaukroger, K.; Hadfield, J. A.; Hepworth, L. A.; Lawrence, N. J.; McGown, A. T. Novel synthesis of cis and trans isomers of combretastatin A-4 J. Org. Chem. 2001, 66, 8135-8138 (Pubitemid 34177965)
23. Handy, S. T.; Zhang, Y. A simple guide for predicting regioselectivity in the coupling of polyhaloheteroaromatics Chem. Commun. 2006, 299-301
24. Nguyen, T. L.; McGrath, C.; Hermone, A. R.; Burnett, J. C.; Zaharevitz, D. W.; Day, B. W.; Wipf, P.; Hamel, E.; Gussio, R. A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach J. Med. Chem. 2005, 48, 6107-6116 (Pubitemid 41324618)
25. Kong, Y.; Grembecka, J.; Edler, M. C.; Hamel, E.; Mooberry, S.; Sabat, M.; Rieger, J.; Brown, M. L. Structure-based discovery of a boronic acid bioisostere of combretastatin A-4 Chem. Biol. 2005, 12, 1007-1014 (Pubitemid 41338811)
26. Tron, G. C.; Pagliai, F.; Del Grosso, E.; Genazzani, A. A.; Sorba, G. Synthesis and cytotoxic evaluation of combretafurazans J. Med. Chem. 2005, 48, 3260-3268 (Pubitemid 40628046)
27. Minotti, A. M.; Barlow, S. B.; Cabral, F. Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin J. Biol. Chem. 1991, 266, 3987-3994 (Pubitemid 21909306)
28. Evans, D. C.; Watt, A. P.; Nicoll-Griffith, D. A.; Baillie, T. A. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development Chem. Res. Toxicol. 2004, 17, 3-16 (Pubitemid 38134055)
29. Ravelli, R. B.; Gigant, B.; Curmi, P. A.; Jourdain, I.; Lachkar, S.; Sobel, A.; Knossow, M. Insight into tubulin regulation from a complex with colchicines and a stathmin-like domain Nature 2004, 428, 198-202 (Pubitemid 38374318)
30. Zhang, W.; Yang, Q.; Wu, Y.; Wu, L.; Li, W.; Qiao, F.; Bao, K.; Zhang, L. Preparation of 2,3-Diarylthiophene Derivatives As Antitumor Agents. CN Patent 101429189, 2009. At least nine synthetic steps are required to prepare the thiophene analogues of combretastatin reported in this patent.
31. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function J. Comput. Chem. 1998, 19, 1639-1662 (Pubitemid 128590223)
32. Riechelmann, R. P.; Del Giglio, A. Drug interactions in oncology: how common are they? Ann. Oncol. 2009, 12, 1907-1912
33. Leandro-Garcia, L. J.; Leskela, S.; Landa, I.; Montero-Conde, C.; Lopez-Jiménez, E.; Leton, R.; Cascon, A.; Robledo, M.; Rodriguez-Antona, C. Tumoral and tissue-specific expression of the major human β-tubulin isotyoes Cytoskeleton 2010, 67, 214-223